Why Jim Cramer Suggests Selling Half of Your Allergan (AGN) Position

NEW YORK (TheStreet) -- TheStreet's Jim Cramer questions if Allergan  (AGN) can fight off Valeant  (VRX), and he will talk to Allegan CEO David Pyott on Wednesday.

Cramer thinks it is clear that Allergan is basing much of its independence on its pipeline, but he believes investors would take their money and run if this pipeline turns out to be not as good as Pyott has claimed.

Cramer suggests investors sell half of their position in Allergan and let the other half run. He thinks the stock would be closed to $120 or $125 if Valeant were not involved. 

Must Watch: Jim Cramer: Allergan Would be at $120 if Valeant Wasn't Involved

 
AGN Chart

AGN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers